Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials.

In patients receiving dupilumab 300 mg q2w + TCS ( n = 16), an arm that was by design one‐third the size of the placebo and q2w arms, the difference compared with placebo did not reach statistical significance at week 16 or week 52.

also in 111,027 other papers